Seer Inc
NASDAQ:SEER
Seer Inc
Research & Development
Seer Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Seer Inc
NASDAQ:SEER
|
Research & Development
-$50.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Research & Development
-$1.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Danaher Corp
NYSE:DHR
|
Research & Development
-$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Waters Corp
NYSE:WAT
|
Research & Development
-$195.7m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Research & Development
-$454m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-4%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Seer Inc
Glance View
Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 118 full-time employees. The company went IPO on 2020-12-04. The firm enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software. Its Proteograph provides a workflow, which enables proteomic profiling and the analysis of samples needed to characterize the nature of the proteome. The Company’s Proteograph consumables consist of its NP panel and other consumables necessary to assay samples on its SP100 automation instrument. Its SP100 automation instrument is custom-configured liquid handling workstation. The firm's Proteograph Instrument Control Software (PICS) for the SP100 instrument is fixed and designed to its specified workflow.
See Also
What is Seer Inc's Research & Development?
Research & Development
-50.6m
USD
Based on the financial report for Dec 31, 2024, Seer Inc's Research & Development amounts to -50.6m USD.
What is Seer Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-32%
Over the last year, the Research & Development growth was 5%. The average annual Research & Development growth rates for Seer Inc have been -20% over the past three years , -32% over the past five years .
